• PCN97 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN THE UKWHO PROGRESS ON TRASTUZUMAB AND HAVE PREVIOUSLY RECEIVED AN ANTHRACYCLINE AND ATAXANE- A NEED FOR EVIDENCE BASED THERAPIES?

    Nov 1, 2008, 00:00

  • PCN101 RELATIONSHIP BETWEEN HEALTH CARE SUPPLY AND MAMMOGRAPHY SCREENING?

    Nov 1, 2008, 00:00

  • PND10 BURDEN OF DISEASE IN MODERATE ALZHEIMER DISEASE PATIENTS WITH DEPRESSION IN SPAIN (IDEAL STUDY)

    Nov 1, 2008, 00:00

  • PIH20 WEIGHT-RELATED MORBIDITY AND FAMILY DISRUPTION FOLLOWING PEDIATRIC EMERGENCY DEPARTMENT TREATMENT (PED) OF ACUTE MINOR INJURY

    Nov 1, 2008, 00:00

  • PCV20 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND STATINS IN A DYSLIPIDEMIA PATIENT COHORT

    Nov 1, 2008, 00:00

  • Bayesian Meta-Analysis of Multiple Treatment Comparisons- An Introduction to Mixed Treatment Comparisons

    Sep 1, 2008, 00:00

  • The Estimation Power of Alternative Comorbidity Indices

    Sep 1, 2008, 00:00

  • Variable Access to Clopidogrel in a Harmonized EU Market

    Sep 1, 2008, 00:00

  • How Inducing Covariation in Simulated HDL-C, Triglyceride, and Total Cholesterol Data Affects Framingham Risk Equation Results

    Sep 1, 2008, 00:00

  • Cost-Effectiveness of HIV Screening of Blood Donations in Accra (Ghana)

    Sep 1, 2008, 00:00

  • Self-Reported Adverse Events after Groin Hernia Repair, A Study Based on a National Register

    Sep 1, 2008, 00:00

  • Optimal Cost-Effectiveness Decisions- The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI)

    Sep 1, 2008, 00:00

  • Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy

    Sep 1, 2008, 00:00

  • Quantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV

    Sep 1, 2008, 00:00

  • Using Cost-Effectiveness Analysis to Sharpen Formulary Decision-Making- The Example of Tiotropium at the Veterans Affairs Health Care System

    Sep 1, 2008, 00:00

  • An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom

    Sep 1, 2008, 00:00

  • Further Validation of an Individualized Migraine Treatment Satisfaction Measure

    Sep 1, 2008, 00:00

  • Lipid Testing among Patients Beginning Statin Therapy in General Practice in the United Kingdom

    Sep 1, 2008, 00:00

  • Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively- A Cost-Effectiveness Analysis

    Sep 1, 2008, 00:00

  • Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland

    Sep 1, 2008, 00:00

  • Household Demand for Preventive HIV/AIDS Vaccines in Thailand- Do Husbands' and Wives' Preferences Differ?

    Sep 1, 2008, 00:00

  • Methodological Considerations in Cost of Prostate Cancer Studies- A Systematic Review

    Sep 1, 2008, 00:00

  • Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease- A Payor Perspective

    Sep 1, 2008, 00:00

  • Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA

    Sep 1, 2008, 00:00

  • Development and Validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q)

    Sep 1, 2008, 00:00

  • Parallel Trade of Pharmaceuticals- A Review of Legal, Economic, and Political Aspects

    Sep 1, 2008, 00:00

  • The Effect of Atrial Fibrillation on Stroke-Related Inpatient Costs in Sweden- A 3-Year Analysis of Registry Incidence Data from 2001

    Sep 1, 2008, 00:00

  • Cost-Effectiveness of LTBI Treatment for TB Contacts in British Columbia

    Sep 1, 2008, 00:00

  • Indirect Costs of Rheumatoid Arthritis in Brazil

    Sep 1, 2008, 00:00

  • Difficulties in Calculating Productivity Costs- Work Disability Associated with Borderline Personality Disorder

    Jul 1, 2008, 00:00

  • Deterioration of Quality of Life of High-Risk Breast Cancer Patients Treated with High-Dose Chemotherapy- The PEGASE 01 Quality of Life Study

    Jul 1, 2008, 00:00

  • Clustering of Cardiovascular Disease Risk Factors and Health-Related Quality of Life among US Adults

    Jul 1, 2008, 00:00

  • Preference-Based Quality of Life of Patients on Renal Replacement Therapy- A Systematic Review and Meta-Analysis

    Jul 1, 2008, 00:00

  • Service Utilization and Health-Care Costs in the Advanced Elderly

    Jul 1, 2008, 00:00

  • Development of EMPRO- A Tool for the Standardized Assessment of Patient-Reported Outcome Measures

    Jul 1, 2008, 00:00

  • Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease

    Jul 1, 2008, 00:00

  • Psychometric Validation of the Cancer Therapy Satisfaction Questionnaire

    Jul 1, 2008, 00:00

  • Understanding Medication Compliance and Persistence from an Economics Perspective

    Jul 1, 2008, 00:00

  • The Effect of Perceived Health Status on Patient Satisfaction

    Jul 1, 2008, 00:00

  • Health-Related Quality of Life Measures for Children and Adolescents with Epilepsy- A Response to Comments

    Jul 1, 2008, 00:00

  • Cost-Effectiveness Model for Neovascular Age-Related Macular Degeneration- Comparing Early and Late Treatment with Pegaptanib Sodium Based on Visual Acuity

    Jul 1, 2008, 00:00

  • A Randomized Controlled Trial of the Cost-Utility of Second-Generation Antipsychotics in People with Psychosis and Eligible for Clozapine

    Jul 1, 2008, 00:00

  • Introducing Evidence-Based Medicine in Reimbursement Procedures- Does It Affect the Outcome?

    Jul 1, 2008, 00:00

  • The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making- To Lambda and Beyond

    Jul 1, 2008, 00:00

  • A Cost-Benefit Analysis Using Contingent Valuation Techniques- A Feasibility Study in Spinal Surgery

    Jul 1, 2008, 00:00

  • Factorial Invariance of Child Self-Report across Age Subgroups- A Confirmatory Factor Analysis of Ages 5 to 16 Years Utilizing the PedsQL 4.0 Generic Core Scales

    Jul 1, 2008, 00:00

  • The Hanover Consensus- Helpful for German Decision-Makers?

    Jul 1, 2008, 00:00

  • Comments on Health-Related Quality of Life Measures for Children and Adolescents with Epilepsy

    Jul 1, 2008, 00:00

  • Scientific Guidelines and Their Implementation in Health Policy

    Jul 1, 2008, 00:00

  • German Recommendations on Health Economic Evaluation- Third and Updated Version of the Hanover Consensus

    Jul 1, 2008, 00:00

  • The Direct Medical Costs of Undiagnosed Chronic Obstructive Pulmonary Disease

    Jul 1, 2008, 00:00

  • Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population

    Jul 1, 2008, 00:00

  • Economic Burden of Adult Pharyngitis- The Payer's Perspective

    Jul 1, 2008, 00:00

  • Costs and Effects of Various Analgesic Treatments for Patients with Rheumatoid Arthritis and Osteoarthritis in The Netherlands

    Jul 1, 2008, 00:00

  • The KIDSCREEN-52 Quality of Life Measure for Children and Adolescents- Psychometric Results from a Cross-Cultural Survey in 13 European Countries

    Jul 1, 2008, 00:00

  • Health-Related Quality of Life Measurement in Children and Adolescents- A Systematic Review of Generic and Disease-Specific Instruments

    Jul 1, 2008, 00:00

  • Survey Assessment of Continuation of and Satisfaction with Pharmacological Treatment for Urinary Incontinence

    Jul 1, 2008, 00:00

  • PCV52 ECONOMIC IMPACT OF A PHYSICIAN-PHARMACIST COLLABORATIVE CARE INTERVENTION IN PRIMARY CARE FOR PATIENTS WITH DYSLIPIDEMIA A CLUSTER-RANDOMISED CONTROLLED TRIAL (TEAM STUDY)

    May 1, 2008, 00:00

  • PIN33 A DYNAMIC MODEL FOR ASSESSING THE IMPACT OF EMERGING VACCINE TECHNOLOGIES ON MEASLES DISEASE BURDEN IN DEVELOPING COUNTRIES

    May 1, 2008, 00:00

  • PMH49 EARLY DISCONTINUATION ONTREATMENT AND ITS CONSEQUENCES IN PATIENTS TREATED WITH VENLAFAXINE OR ESCITALOPRAM

    May 1, 2008, 00:00

  • PHP43 PHYSICIANS VIEWS REGARDING THE IMPACT OF MEDICARE PART D DRUG COVERAGE FOR DUAL-ELIGIBLE PATIENTS

    May 1, 2008, 00:00

  • PMH55 MEDICATION COMPLIANCE IN THOSE WITH SCHIZOPHRENIA RECEIVING PSYCHIATRIC SERVICES FROM AVETERANS HOSPITAL INTAIWAN

    May 1, 2008, 00:00

  • PRS26 PREFERENCES FOR ONSET OF EFFECT OF COMBINATION MAINTENANCE MEDICATION AMONG ASTHMA PATIENTS

    May 1, 2008, 00:00

  • PIH2 CONTRACEPTIVE FAILURE RATES AMONG MEDICAID AND NON-MEDICAID ENROLLEES

    May 1, 2008, 00:00

  • PMS33 RELATIONSHIP BETWEEN PATIENTS COMPLIANCE TO MS SPECIALTY MEDICATIONS AND TOTAL HEALTH CARE COSTS

    May 1, 2008, 00:00

  • PSY3 A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS OFTHE EFFICACY OF BOTULINUM TOXIN A FOR THE PROPHYLAXIS OF CHRONIC MIGRAINE HEADACHES

    May 1, 2008, 00:00

  • PMC34 INTERNATIONAL SURVEY ONWTP FOR ONE ADDITIONAL QALY GAIN-HOW MUCH IS THE THRESHOLD OF COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PIN7 MRSA- INVESTIGATING THE DANGEROUS HOSPITAL INFECTION

    May 1, 2008, 00:00

  • PMS5 WHAT HAPPENED TO VIOXX USERS?

    May 1, 2008, 00:00

  • PSY11 EVALUATION OF ACETAMINOPHEN EXPOSURES REPORTED TO A REGIONAL POISON CONTROL CENTER FOR ADULT PATIENTS

    May 1, 2008, 00:00

  • PCN45 RESOURCE UTILIZATION AND COST ESTIMATION OF ADVERSE EVENTS OF NON-SMALL CELL LUNG CANCER TREATMENT IN MEXICAN PATIENTS. RESULTS OF A DELPHI PANEL

    May 1, 2008, 00:00

  • PSY19 PHARMACOECONOMIC EVALUATION OF TREATMENT OF HAIRY CELL LEUKEMIA

    May 1, 2008, 00:00

  • PND2 THE FABRY OUTCOME SURVEY (FOS)- A DATABASE OF PROSPECTIVE OBSERVATIONS ONTHE NATURAL HISTORY AND MANAGEMENT OF A RARE DISEASE

    May 1, 2008, 00:00

  • PSY44 LINGUISTIC VALIDATION OF THE HAEMO-QOL AND HAEM-A-QOL FOR USE IN INTERNATIONAL STUDIES

    May 1, 2008, 00:00

  • PMH84 PREDICTORS OFTREATMENT INITIATION OF DULOXETINE VS. VENLAFAXINE XR FOR PATIENTS WITH MAJOR DEPRESSION DISORDER IN MANAGED CARE SETTINGS

    May 1, 2008, 00:00

  • PND23 MIGRAINE SUFFERERS SHOW SIGNIFICANT HEALTH CARE UTILIZATION AND EXPENDITURES

    May 1, 2008, 00:00

  • PCN15 MODELING THE COST IMPACT OF POSSIBLE CROSS-PROTECTION DIFFERENCES OF TWO CERVICAL CANCERVACCINES IN CANADA USING MULTIPLE PROBABILISTIC SENSITIVITY ANALYSIS

    May 1, 2008, 00:00

  • PDB78 MEASURING THE IMPACT OF AN EDUCATIONAL PROGRAM ON PHYSICIAN PRACTICE PATTERNS- EXPERTMD(tm) CV DIABETES

    May 1, 2008, 00:00

  • PCV2 STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED ACCORDINGTO NATIONAL LIPID TREATMENT GUIDELINES

    May 1, 2008, 00:00

  • PDB62 DETERMINANTS OF INSULIN INITIATION FOR PATIENTS WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PMC41 MAPPING SF-12 TO EUROQOL EQ-5D PREFERENCE SCORES IN THE SPANISH-SPEAKING HISPANIC COMMUNITY IN THE UNITED STATES

    May 1, 2008, 00:00

  • PSY39 HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH HEMOPHILIA AND INHIBITORS

    May 1, 2008, 00:00

  • PRS3 AVALIDATION STUDY ON USING MORTALITY RISK STRATIFICATION TOOL TO STRATIFY ECONOMIC RISK IN PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AECOPD)

    May 1, 2008, 00:00

  • PMC10 THE DEVELOPMENT OF COST-EFFECTIVENESS INDICES WITH EQUITY IMPLICATIONS FOR THE ECONOMIC EVALUATION OF HEALTH CARE

    May 1, 2008, 00:00

  • HP2 NHS REIMBURSEMENT OF NEW CANCER DRUGS- IS NICE GETTING NASTIER?

    May 1, 2008, 00:00

  • PCV25 IMPROVEMENTS IN CARDIOVASCULAR DISEASE OUTCOMES IN MANAGED CARE PATIENTS MANAGED ACCORDING TO NATIONAL LIPID TREATMENT GUIDELINES

    May 1, 2008, 00:00

  • PMH2 BENCHMARKING SCHIZOPHRENIA WITH A FOCUS ON PHARMACOTHERAPYAND METABOLIC SYNDROME

    May 1, 2008, 00:00

  • PND45 USE OF DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS- A POPULATION BASED STUDY

    May 1, 2008, 00:00

  • PDB19 ECONOMIC EVALUATION OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF SHORT CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA)

    May 1, 2008, 00:00

  • PMH60 HEALTH STATUS ANDWORK-RELATED OUTCOMES OF PATIENTS WITH ANXIETY DISORDERS AND DEPRESSION

    May 1, 2008, 00:00

  • PUK10 ECONOMIC EVALUATION OF POLYCLONAL ANTIBODIES FOR THE MANAGEMENT OF HIGH RISK PATIENTS WITH ACUTE REJECTION IN RENAL TRANSPLANTATION AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2008, 00:00

  • PCV27 COST EFFECTIVENESS STUDIES IN HEART FAILURE- AN UPDATE OF THE LITERATURE

    May 1, 2008, 00:00

  • PCV105 IMPACT OF GUIDELINES FORTREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN COMMUNITY HOSPITALS

    May 1, 2008, 00:00

  • PCV4 APPROPRIATE UTILIZATION AND COST-ANALYSIS OF ADD-ON EZETIMBE LIPID-LOWERING THERAPY AT THE VETERANS AFFAIRS SAN DIEGO HEALTH CARE SYSTEM (VASDHS)

    May 1, 2008, 00:00

  • PMH11 ASSESSING THE REPORTING AND SCIENTIFIC QUALITY OF META-ANALYTIC RESEARCH SYNTHESISING RANDOMIZED CONTROLLED TRIALS FOR ANXIETY DISORDER TREATMENTS

    May 1, 2008, 00:00

  • PMH31 A PHARMACOECONOMIC ANALYSIS OF SCHIZOPHRENIC PATIENTS SWITCHING FROM BRANDED TO GENERIC RISPERIDONE INVOLVING A POSSIBLE COMPLIANCE LOSS

    May 1, 2008, 00:00

  • PUK20 IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE WITH FESOTERODINE- KINGS HEALTH QUESTIONNAIRE ITEM ANALYSIS

    May 1, 2008, 00:00

  • PND27 RELATIONSHIP BETWEEN GAPS IN DRUGTREATMENT FOR MULTIPLE SCLEROSIS AND INCIDENCE OF EXACERBATIONS- FINDINGS FROM A NATIONAL MANAGED CARE DATABASE

    May 1, 2008, 00:00

  • PMS13 COST EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW

    May 1, 2008, 00:00

  • PSY25 ECONOMIC IMPACT AND CONSERVATION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG)THROUGHTHERAPEUTIC SUBSTITUTION WITH ANTI-D IN PATIENTS WITH IDIOPATHICTHROMBOCYTOPENIA PURPURA (ITP) AT AN URBANTEACHING HOSPITAL IN STATEN ISLAND, NY

    May 1, 2008, 00:00

  • PMC4 THE ADOPTION AND DIFFUSION OF COST-EFFECTIVENESS ACCEPTABILITY CURVES IN PUBLISHED ECONOMIC EVALUATIONS

    May 1, 2008, 00:00

  • DU2 DOES COMMUNITY-BASED HEALTH INSURANCE IMPROVE ACCESS TO DRUGS AND HEALTH CARE FORTHE POOREST IN AFRICA?

    May 1, 2008, 00:00

  • PMH83 USING RETAIL PHARMACY PRESCRIPTION DATATO INVESTIGATE THE SEASONALITY OF ADHDTREATMENT- JANUARY 2003-OCTOBER 2007

    May 1, 2008, 00:00

  • PSY53 HOSPITAL CHARGES AND COMORBIDITIES AMONG OBESE AND MORBIDLY OBESE PATIENTS

    May 1, 2008, 00:00

  • A Longitudinal Analysis of Outcomes Associated with Abciximab and Eptifibatide in a Consecutive Series of 3074 Percutaneous Coronary Interventions

    May 1, 2008, 00:00

  • PND8 MEDICAL COSTS ASSOCIATED WITHTREATMENT CHANGE IN MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PMS44 PRESCRIPTION TREATMENT PATTERNS IN PATIENTS WITH CHRONIC OSTEOARTHRITIS PAIN

    May 1, 2008, 00:00

  • CASE 6 THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY TO IMPROVE QUALITY INTHEACUTE CARE SETTING

    May 1, 2008, 00:00

  • PSS41 APPLES AND ORANGES? ASSESSING THE RELATIONSHIP BETWEEN HEALTH AND VISION RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PCV11 ASSESSMENT AND QUANTIFICATION OF THE BENEFIT RISK RATIO OF ROSUVASTATIN AND ATORVASTATIN FROM A META-ANALYSIS OF HEAD TO HEAD RANDOMISED CONTROLLED TRIALS

    May 1, 2008, 00:00

  • PHC4 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES OVER I YEARAFTER TOTAL HIP REPLACEMENT IN VETERAN PATIENTS

    May 1, 2008, 00:00

  • PMH73 INITIATION OF ATOMOXETINE VS. STIMULANTS FOR CHILDREN WITH ADHD IN MEDICAID SETTINGS

    May 1, 2008, 00:00

  • PND3 TRENDS IN THE PREVALENCE OF AUTISM SPECTRUM DISORDERS AND RELATED HEALTH CARE UTILIZATION AND COSTS IN A STATE MEDICAID PROGRAM

    May 1, 2008, 00:00

  • PCN57 COST-UTILITY ANALYSIS OF ADJUVANT GOSERELIN AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH PREMENOPAUSAL BREAST CANCER

    May 1, 2008, 00:00

  • PHP48 THE STATE OF HEALTH ECONOMICS AND PHARMACOECONOMICS EVALUATION RESEARCH IN ZIMBABWE

    May 1, 2008, 00:00

  • PHP30 COST-EFFECTIVENESS ANALYSIS AND RETURN ON INVESTMENT OF HIGH COST PATIENTS MANAGEMENT PROGRAMWITHIN A PRIVATE HEALTH CARE PLAN IN BRAZIL

    May 1, 2008, 00:00

  • PND33 IMPROVED QUALITY OF LIFE AMONG RELAPSINGREMITTING MULTIPLE SCLEROSIS PATIENTS TREATED LONG-TERM WITH GLATIRAMER ACETATE

    May 1, 2008, 00:00

  • PGI21 A COMPARISON OF TEST-RETEST RELIABILITY OF SELF-REPORTED SF-36, WHOQOL, AND EQ-5D QUESTIONNAIRES BASED ON DIFFERENT ADMINISTRATION APPROACHES

    May 1, 2008, 00:00

  • PIN49 SPREAD PATTERN FORMATION OF H5NI-AVIAN INFLUENZA AND ITS IMPLICATIONS FOR CONTROL STRATEGIES

    May 1, 2008, 00:00

  • PCV76 LONGITUDINAL ASSESSMENT OF THE CLINICAL UTILITY OF POINT-OF-CARE MEASUREMENT DEVICES FOR DETERMINING THE INTERNATIONAL NORMALIZED RATIO

    May 1, 2008, 00:00

  • PSY22 COST-EFFECTIVENESS OF PREGABALIN COMPARED TO GABAPENTIN INTREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA

    May 1, 2008, 00:00

  • PSY1 META-ANALYSIS OF ANTICONVULSANTS, SNRIS ANDTCAS IN TREATING NEUROPATHIC PAIN

    May 1, 2008, 00:00

  • PDB32 ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OFACROMEGALY IN MEXICO

    May 1, 2008, 00:00

  • PCN27 COST-EFFECTIVENESS ANALYSIS OF SCREENING SUBJECTS WITH DIFFERENT LEVELS OF RISK FOR HEPATOCELLULAR CARCINOMA IN TAIWAN

    May 1, 2008, 00:00

  • PSY24 THE ECONOMIC CONSEQUENCES OF POST OPERATING PAIN MANAGEMENT WITHTRANSDERMAL FENTANYL (IONSYS) VERSUS INTRAVENOUS PATIENT-CONTROLLED ANALGESIA

    May 1, 2008, 00:00

  • PHP76 ALBERTAS HEALTH SYSTEM PERFORMANCES BALANCED SCORECARD STUDY

    May 1, 2008, 00:00

  • PHC6 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN HUNGARY

    May 1, 2008, 00:00

  • PCN74 WILL KNOWLEDGE OF GENETIC RISK FOR CANCER INFLUENCE QUALITY OF LIFE AND SCREENING BEHAVIOR? FINDINGS FROM A POPULATION-BASED STUDY

    May 1, 2008, 00:00

  • PCV28 CARDIOVASCULAR EVENT DRIVEN ECONOMIC ANALYSIS OF ROSUVASTATIN VERSUS SIMVASTATIN USING PRAGMATIC HEAD-TO-HEAD RCTSWITH SURROGATE END-POINT MEASURES

    May 1, 2008, 00:00

  • PRS36 FACTORS ASSOCIATED WITH ANTIHISTAMINE PRESCRIBING IN ASTHMA IN THE UNITED STATES IN 2005

    May 1, 2008, 00:00

  • PMH6 OPTIMAL THRESHOLDS OF EARLY NON-RESPONSE TO ATYPICAL ANTIPSYCHOTICS- APPLICATION OF SIGNAL DETECTION ANALYSIS

    May 1, 2008, 00:00

  • PCV91 PATIENT INSURANCE AND MEDICATION CHOICE FOR HYPERCHOLESTEROLEMIA

    May 1, 2008, 00:00

  • PCN96 REAL WORLD TREATMENT PATTERNS IN HIGH RISK OR METASTATIC MELANOMA- EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE

    May 1, 2008, 00:00

  • MD3 IMPACT OF MEDICARE PART D DOUGHNUT HOLE ONTHE USE OF MEDICATIONS BY THERAPEUTIC CLASSES FOR STANDARD BENEFICIARIES

    May 1, 2008, 00:00

  • PUK17 ECONOMIC EVALUATION OF SEVELAMER VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS ON DIALYSIS IN THE UNITED KINGDOM SETTING

    May 1, 2008, 00:00

  • PCV37 BIATRIAL VERSUS RIGHT ATRIAL APPENDAGE PACING IN BRADYCARDIA TACHYCARDIA SYNDROME

    May 1, 2008, 00:00

  • PMH44 HEALTH CARE RESOURCE UTILIZATION AND COSTS COMPARISON FOR MDD PATIENTS ON 10 MG ESCITALOPRAMWHO INCREASED TO 20 MG DOSE VS. THOSEWHOWERE SWITCHED TO SNRI

    May 1, 2008, 00:00

  • PMS46 TREATMENTS FOR UPPER-LIMB POST-STROKE SPASTICITY- A CRITICAL EVALUATION

    May 1, 2008, 00:00

  • OM1 VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSETHEORY- APPLICATION OF KERNEL REGRESSION

    May 1, 2008, 00:00

  • PSY29 THE DIRECT AND INDIRECT COSTS OF OBESITY IN AN EMPLOYED POPULATION

    May 1, 2008, 00:00

  • PMH59 HEALTH RELATED QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS- RESULTS AT BASELINE FROM THE COMETA STUDY

    May 1, 2008, 00:00

  • PM1 RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2008, 00:00

  • PCN63 RACIAL DIFFERENCES IN MEDICATION ADHERENCE TO ADJUVANT HORMONAL THERAPY IN MEDICAID ENROLLED WOMEN WITH PRIMARY BREAST CANCER- A COMPARISON USING TWO ESTIMATION METHODOLOGIES

    May 1, 2008, 00:00

  • PCN60 EFFECT OF DEMOGRAPHIC FACTORS AND SOCIAL ECONOMIC VARIABLES ON HEALTH CARE RESOURCE UTILIZATION AND EXPENDITURE FOR BREAST CANCER PATIENTS USING MEPS 2001

    May 1, 2008, 00:00

  • PMH46 PREDICTORS OF MEDICATION ADHERENCE AMONG SCHIZOPHRENIA PATIENTS TREATED WITH CONVENTIONAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM

    May 1, 2008, 00:00

  • PMC39 A COMPREHENSIVE PARADIGM TO ESTIMATE MINIMAL CLINICALLY IMPORTANT DIFFERENCES (MCID)

    May 1, 2008, 00:00

  • PMH17 METABOLIC MONITORING AMONG SCHIZOPHRENIA PATIENTS INITIATED ON ATYPICAL ANTIPSYCHOTICS IN THE VETERAN HEALTH ADMINISTRATION

    May 1, 2008, 00:00

  • PHP44 SOURCES OF MEDICAL INFORMATION AND DEGREE OF TRUST PLACED IN THEM BY RUSSIAN DOCTORS

    May 1, 2008, 00:00

  • PDB15 COSTS OF PEN (NOVOPEN(r) 3)VERSUS SYRINGE IN THE TREATMENT OF DIABETES MELLITUSTYPE 2- A PHARMACOECONOMIC STUDY FROM THE SLOVAK REPUBLIC

    May 1, 2008, 00:00

  • PHP31 DRUG PROXIES FOR IDENTIFYING SPECIFIC DIAGNOSES IN MEDICARE PART D

    May 1, 2008, 00:00

  • DB4 RETROSPECTIVE STUDY OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS NOT OPTIMALLY CONTROLLED BY METFORMIN MONOTHERAPY

    May 1, 2008, 00:00

  • PMS12 COST-EFFECTIVENESS ANALYSIS OF ZOLEDRONIC ACID VERSUS RISEDRONATE FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURE IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL

    May 1, 2008, 00:00

  • PCV39 INDIRECT COMPARISONS OF RIVAROXABAN VS ALTERNATIVE PROPHYLAXES FORTHE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP ORTOTAL KNEE REPLACEMENT

    May 1, 2008, 00:00

  • PHP78 STABILITY OF PHYSICIAN PERFORMANCE ON PAY-FOR-PERFORMANCE PROCESS MEASURES OVERTIME- EFFECT OF PATIENT DENOMINATOR THRESHOLDS

    May 1, 2008, 00:00

  • PRS37 CONCURRENT ASTHMA CONTROLLER MEDICATION POSSESSION PROFILES IN AN ADULT MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PND43 LEVEL OF SATISFACTION OF SPANISH MULTIPLE SCLEROSIS PATIENTS TREATED WITH A NEW FORMULATION OF AVONEX (INTERFERON BETA-1A 30 MCG INTRAMUSCULAR, ONCE WEEKLY, SOLUTION FOR INJECTION READY TO USE)

    May 1, 2008, 00:00

  • PHP23 SPECIALTY BIOLOGIC DRUG COVERAGE UNDER MEDICARE PART D-THE EXPERIENCE OFVULNERABLE BENEFICIARIES WITH RHEUMATOID ARTHRITIS (RA) AND MULTIPLE SCLEROSIS (MS)

    May 1, 2008, 00:00

  • PND39 PATIENT- AND PHYSICIAN-ASSESSED FUNCTIONAL DISABILITY IN PATIENTS TREATED WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA

    May 1, 2008, 00:00

  • PDB49 INFLUENCE OF FAMILY STRUCTURE ON EMERGENCY ROOM UTILIZATION OF DIABETIC MOTHERS

    May 1, 2008, 00:00

  • PRS35 A STATISTICAL LOOK AT COPD

    May 1, 2008, 00:00

  • PCN50 THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA

    May 1, 2008, 00:00

  • PHP45 COMMON DRUG REVIEW (CDR) RECOMMENDATIONS- DOES COST-EFFECTIVENESS MATTER?

    May 1, 2008, 00:00

  • PGI17 ADHERENCE TO INFLIXIMAB MAINTENANCE THERAPY AND ITS IMPACT ON HOSPITALIZATION OF PATIENTS WITH CROHNS DISEASE

    May 1, 2008, 00:00

  • PSY8 THE ECONOMIC BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS AMONG PATIENTS OFTHE CAROLINA LUPUS STUDY EARLY INTHE COURSE OF DISEASE

    May 1, 2008, 00:00

  • PSY48 IMPACT OF IMMUNETHROMBOCYTOPENIC PURPURA ON HEALTH CARE RESOURCE USE ANDWORKPLACE PRODUCTIVITY

    May 1, 2008, 00:00

  • PCN53 THE BURDEN OF MANAGING PLEURAL EFFUSIONS IN CML PATIENTS POST-IMATINIB FAILURE-A LITERATURE-BASED ECONOMIC ANALYSIS

    May 1, 2008, 00:00

  • PHP57 FACTOR ANALYSIS OF PHARMACISTS PERCEIVED BARRIERS TO PROVISION OF MEDICATION THERAPY MANAGEMENT SERVICES (MTMS) IN WEST VIRGINIA

    May 1, 2008, 00:00

  • Duration of Antipsychotic Drug Therapy in Real-World Practice- A Comparison with CATIE Trial Results

    May 1, 2008, 00:00

  • PHC9 THE POTENTIAL SAVINGS IN OPERATING ROOM TIME ASSOCIATED WITH THE USE OF SUGAMMADEXTO REVERSE SELECTED NEUROMUSCULAR BLOCKING AGENTS- FINDINGS FROM A HOSPITAL EFFICIENCY MODEL

    May 1, 2008, 00:00

  • PMH74 IMPACT OF ALTERNATIVE TREATMENTS ON POST TREATMENT COSTS FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PMH14 DIFFERENTIAL EFFECTS OF OLANZAPINE AND CLOZAPINE ON TYPE II DIABETES- FINDINGS FROM A CLAIMS DATABASE

    May 1, 2008, 00:00

  • PCN7 ANALYSIS OF MASTECTOMY IN BREAST CANCER TREATMENT

    May 1, 2008, 00:00

  • PCV73 VALIDATION OF AN ABBREVIATED TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM-9) AMONG PATIENTS ON ANTIHYPERTENSIVE MEDICATIONS

    May 1, 2008, 00:00

  • PCN87 USE OF PHARMACOECONOMIC MESSAGES IN ONCOLOGY PROMOTIONAL MATERIALS

    May 1, 2008, 00:00

  • PMH37 UNITED KINGDOM COST-CONSEQUENCE ANALYSIS OF ARIPIPRAZOLE IN SCHIZOPHRENIA- DIABETES AND CORONARY HEART DISEASE RISK PROJECTIONS (STAR STUDY)

    May 1, 2008, 00:00

  • PSY35 PREVALENCE OF METABOLIC SYNDROME AND ITS IMPACT ON HEALTH CARE RESOURCE UTILIZATION

    May 1, 2008, 00:00

  • PIH24 AN ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE DUALLY ELIGIBILE MEDICARE AND MEDICAID POPULATION USING THE NEW 2003 BEERS DRUG UPDATE

    May 1, 2008, 00:00

  • PSS25 PHARMACOECONOMIC STUDY OF WET AGE-RELATED MACULAR DEGENERATION (AND)TREATMENT IN MEXICO

    May 1, 2008, 00:00

  • PHP70 PHYSICIANS KNOWLEDGE OF LABELED DRUG INDICATIONS AND ATTITUDES REGARDING OFF-LABEL USE- RESULTS OF A NATIONAL SURVEY OF GENERAL INTERNISTS AND PSYCHIATRISTS

    May 1, 2008, 00:00

  • PMC25 SENSITIVITY ANALYSIS FOR PROPENSITY SCORE MATCHING

    May 1, 2008, 00:00

  • PCV16 PERMANENT STRESS MAY BE THE TRIGGER OF A HEART ATTACK ON THE FIRST WORK-DAY OF THE WEEK

    May 1, 2008, 00:00

  • PHP7 THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON OUTCOMES AMONG ADULTS INTHE UNITED STATES

    May 1, 2008, 00:00

  • PDB48 LOST PRODUCTIVITY ASSOCIATED WITH TYPE I AND TYPE 2 DIABETES IN A COMMERCIALLY-INSURED POPULATION

    May 1, 2008, 00:00

  • PMH50 MEDICATION ADHERENCE, ETHNICITY, ANDTHE INFLUENCE OF MULTIPLE PSYCHOSOCIAL AND FINANCIAL BARRIERS IN VETERANS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PIH22 CARESS- THE CANADIAN REGISTRY OF SYNAGIS()

    May 1, 2008, 00:00

  • PGI1 HETEROGENEITY ACROSS RANDOMIZED CONTROLLED TRIALS OF PROTON-PUMP INHIBITORS IN NIGHTTIME GERD- A SYSTEMATIC REVIEW

    May 1, 2008, 00:00

  • PHC3 COST-EFFECTIVENESS MODELING OF DENTAL IMPLANT 1ST LINE STRATEGY VERSUS BRIDGE

    May 1, 2008, 00:00

  • PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA

    May 1, 2008, 00:00

  • PCN79 METHODS FOR ASSESSING QUALITY OF LIFE IN CANCER PATIENTS EXPERIENCING COMPLICATIONS- OSTEONECROSIS OF THE JAW PILOT STUDY

    May 1, 2008, 00:00

  • PIN38 RANDOMIZED CONTROLLED TRIAL OF TELEPHONE, EMAIL AND TEXT MESSAGING REMINDERS ON PATIENT COMPLIANCE WITH ANTIBIOTIC REGIMEN

    May 1, 2008, 00:00

  • PRS27 INTERPRETING CLINICAL TRIALS RESULTS FOR THE ONSET OF EFFECT QUESTIONNAIRE- METHODS AND RESULTS OF A DELPHI PANEL

    May 1, 2008, 00:00

  • PSS44 USTEKINUMAB IMPROVES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    May 1, 2008, 00:00

  • PGI16 DISPARITIES IN MEDICATION UTILIZATION AND COMPLIANCE FOR GASTRO-ESOPHAGEAL REFLUX DISEASE- A POPULATION-BASED STUDY

    May 1, 2008, 00:00

  • PMS38 ESTIMATING WORK PRODUCTIVITY- EFFECTS OFTRAMADOL EXTENDED-RELEASE TREATMENT

    May 1, 2008, 00:00

  • PDB76 PROFILING PHYSICIAN PRESCRIPTION BEHAVIORWITH CANONICAL CORRESPONDENCE ANALYSIS

    May 1, 2008, 00:00

  • PRS14 BENEFITS FROM IMPROVED ASTHMA CARE IN FINLAND 1987-2005 ASSESSED WITH ANALYSIS OF COMPREHENSIVE SOCIETAL COST AND BEHAVIOUR OF COST DRIVERS

    May 1, 2008, 00:00

  • PSS16 A COST-EFFECTIVENESS ANALYSIS OF TWO TOPICAL OPHTHALMIC ANTIBIOTIC SOLUTIONS INDICATED FOR THE TREATMENT OF BACTERIAL CONJUNCTIVITIS

    May 1, 2008, 00:00

  • PCV88 OLD HABITS DIE HARD- A NATIONWIDE UTILIZATION STUDY OF CALCIUM CHANNEL BLOCKERS IN TAIWAN

    May 1, 2008, 00:00

  • PSS29 USTEKINUMAB IMPROVES DISEASE SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS- RESULTS WITH THE DERMATOLOGY LIFE QUALITY INDEX

    May 1, 2008, 00:00

  • PIN27 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FORTREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN THE UNITED KINGDOM

    May 1, 2008, 00:00

  • PCV54 THE COST-UTILITY OF ALISKIREN IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. A CANADIAN HEALTH CARE SYSTEM PERSPECTIVE

    May 1, 2008, 00:00

  • PM3 THEVALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACHTO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN

    May 1, 2008, 00:00

  • PIH30 PRIVATE HEALTH INSURANCE VS. MEDICAID COVERAGE- DISPARITIES IN PROCESS OF CARE MEASURES

    May 1, 2008, 00:00

  • PND9 COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA- A US PERSPECTIVE

    May 1, 2008, 00:00

  • PCV26 BELGIAN BUDGET IMPACT ANALYSES OF ALISKIREN (TEKTURNA/RASILEZ) IN HYPERTENSION

    May 1, 2008, 00:00

  • PCV59 THE COST AND EFFECTIVENESS OF ADHERENCE-IMPROVING INTERVENTIONS FOR LIPID-LOWERING AND ANTIHYPERTENSIVE DRUGS

    May 1, 2008, 00:00

  • PUK25 DIALYSIS FACILITY CHARACTERISTICS INFLUENCE THE USE OF HOME DIALYSIS IN THE U.S.

    May 1, 2008, 00:00

  • PDB35 CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • CN3 COMPARISON OFTHE COST-EFFECTIVENESS OF SIX CYCLES OFTAXOTERE, DOXORUBICIN, CYCLOPHOSPHAMIDE (TAC) VERSUS SIX CYCLES OF FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE (FAC) INTHE ADJUVANT SETTING OF NODE POSITIVE BREAST CANCERWITH PRIMARY A ...

    May 1, 2008, 00:00

  • PCN13 BUDGET IMPACT ANALYSIS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CANADA

    May 1, 2008, 00:00

  • PCN92 THE WAR ON CANCER- AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL

    May 1, 2008, 00:00

  • PCV82 EVALUATION OF THE EFFECT OF ACUTE DECOMPENSATED HEART FAILURE GUIDELINES IN COMMUNITY HOSPITALS

    May 1, 2008, 00:00

  • PCN70 THE IMPACT OF HODGKIN S LYMPHOMA ON HEALTH RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PCV104 RELATIONSHIP BETWEEN QUALITY OF CARE AND EXCESSIVE COST FOR MEDICARE PATIENTS UNDERGOING LOWER EXTREMITY BYPASS SURGERY

    May 1, 2008, 00:00

  • DH2 IMPACT OF ADHERING TO LIPID MANAGEMENT NATIONAL GUIDELINE RECOMMENDATIONS ON CARDIOVASCULAR EVENTS AND COSTS IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PMS7 TREATMENT OF DISPLACED FEMORAL NECK FRACTURES IN THE ELDERLYA COST BENEFIT ANALYSIS

    May 1, 2008, 00:00

  • PDB37 FACTORS ASSOCIATED WITH HEALTH CARE COSTS AMONG ELDERLY PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • PRS43 ECONOMIC BURDEN OF ASTHMA AMONG CHILDREN IN THE UNITED STATES

    May 1, 2008, 00:00

  • WH3 CLINICAL AND ECONOMIC OUTCOMESAMONGWOMEN USING LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS)

    May 1, 2008, 00:00

  • MH4 TREATMENT COST AND COMORBIDITIES ASSOCIATEDWITH OBESITY AMONG CHILDREN ANDADOLESCENTSWITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PMC40 PHARMACY STUDENTS PERCEPTIONS OF HEALTH-RELATED QUALITY OF LIFE FOR MULTIPLE CHRONIC HEALTH STATES MEASURED VIA ALTERNATIVE METHODS FOR UTILITY ASSESSMENT

    May 1, 2008, 00:00

  • PCV97 IS THERE A LEARNING CURVE ASSOCIATED WITH EXERCISE TRAINING IN PATIENTS WITH HEART FAILURE?

    May 1, 2008, 00:00

  • PIN45 COMPREHENSIVE EDUCATIONAL APPROACH HOWTO INFLUENCE PRESCRIPTION HABITS AND ANTIBIOTIC RESISTANCE IN AMBULATORY PRACTICE

    May 1, 2008, 00:00

  • PCV45 ECONOMIC IMPACT OF STROKE-RELATED COMORBID CONDITIONS ON THE TREATMENT OF STROKE- AN ANALYSIS OF MEDICARE BENEFICIARIES IN THE UNITED STATES

    May 1, 2008, 00:00

  • PIN15 ECONOMIC EVALUATION OFTIPRANAVIR IN THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

    May 1, 2008, 00:00

  • PCV80 NATIONAL ESTIMATES OF ENROLLMENT IN DISEASE STATE MANAGEMENT PROGRAMS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PCV68 CLINICAL DETERMINANTS OF SATISFACTION AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CARDIAC DISEASE AND DYSLIPIDEMIA

    May 1, 2008, 00:00

  • PMH19 MONOTHERAPYWITH ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIAS CLINICAL REVIEW AND ECONOMIC EVALUATION OF FIRST TWELVE MONTHS OF TREATMENT

    May 1, 2008, 00:00

  • PCV20 UPDATING THE RXRISK-V- CREATING A CROSSWALK BETWEEN VA AND FIRSTDATABANK THERAPEUTIC CATEGORIES

    May 1, 2008, 00:00

  • PCV63 BARRIERS AND MOTIVATORS ASSOCIATED WITH ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS AND BLOOD PRESSURE CONTROL AMONG AFRICAN AMERICANS FROM ALABAMA

    May 1, 2008, 00:00

  • PCV23 MEDICAL CLAIMS FOR GASTROINTESTINAL ADVERSE EVENTS ARE COMMON IN PATIENTS PRESCRIBED CLOPIDOGREL

    May 1, 2008, 00:00

  • PCV74 THE IMPACT OF TARGETED MEMBER EDUCATION ON CHOICE OF PREFERRED STATIN THERAPY AFTER A FORMULARY CHANGE

    May 1, 2008, 00:00

  • PMH10 TREATMENT PATTERNS PRIORTO INITIATING DEPOT TYPICAL ANTIPSYCHOTICS FOR NON-ADHERENT SCHIZOPHRENIA PATIENTS

    May 1, 2008, 00:00

  • PSY31 GREATER SEVERITY OF ILLNESS, RISK OF MORTALITY, LENGTH-OF-STAY, AND HOSPITAL COSTS IN PATIENTS WITH HYPONATREMIA

    May 1, 2008, 00:00

  • DU1 DEMOGRAPHIC RISK FACTORS FOR STROKE RELATED AMBULATORY CARE UTILIZATION-ANALYSIS OF UNITED STATES NATIONAL DATA 2000-2005

    May 1, 2008, 00:00

  • PUK6 FESOTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER-A COST-EFFECTIVENESS CASE STUDY OF SWEDEN

    May 1, 2008, 00:00

  • PSS4 THE RCT EVIDENCE OF COMPARATIVE EFFECTIVENESS AND SAFETY OF TOPICAL GLAUCOMA MEDICATION

    May 1, 2008, 00:00

  • PMH16 METABOLIC SAFETY AND TOLERABILITY OF ZIPRASIDONE VS. OLANZAPINE IN SCHIZOPHRENIA PATIENTS- SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2008, 00:00

  • PSY45 EVALUATION OF THE NEUROPATHIC PAIN SYMPTOM INVENTORY- CONCEPTUAL ADEQUACY IN SIX COUNTRIES

    May 1, 2008, 00:00

  • PMH9 RETENTION RATES FOR ORAL AND DEPOT ANTIPSYCHOTIC MEDICATIONS OVER ONE YEAR IN ONTARIO, CANADA

    May 1, 2008, 00:00

  • PMH33 COST-EFFECTIVENESS OF ARIPIPRAZOLE FOR THE MANAGEMENT OF SCHIZOPHRENIA IN THE UNITED KINGDOM

    May 1, 2008, 00:00

  • PMH21 PHARMACY COST IMPACT OF GUIDELINE-RECOMMENDED DOSING OF SECOND GERNERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA

    May 1, 2008, 00:00

  • AC4 THE COST OF NON-ADHERENCETO ASTHMATREATMENT GUIDELINES AMONG A LOW-INCOME COHORT

    May 1, 2008, 00:00

  • PSS33 INTERNATIONAL DEVELOPMENT OF THE FIRST QUALITY OF LIFE INSTRUMENT SPECIFIC TO COSMETOLOGY AND PHYSICAL APPEARANCE-THE BEAUTYQOL INITIATIVE

    May 1, 2008, 00:00

  • PCASE6 HOW SHOULD NEWTECHNOLOGIES AND NEW DEVICES BE ASSESSED IN A HOSPITAL SYSTEM?

    May 1, 2008, 00:00

  • PCN40 CONTROLLING FOR POTENTIAL CENSORING BIAS ON DEPENDENT VARIABLES

    May 1, 2008, 00:00

  • PSY37 RESOURCE USE AND COSTS ASSOCIATED WITH BACK PAIN IN GERMANY

    May 1, 2008, 00:00

  • PCV31 COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR DIAGNOSIS OF DEEP VEIN THROMBOSIS

    May 1, 2008, 00:00

  • PIN13 ECONOMIC EVALUATION OF POSACONAZOLE VS. STANDARD AZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH PROLONGED NEUTROPENIA IN CANADA

    May 1, 2008, 00:00

  • PCN75 BURDEN OF IMMUNE THROMBOCYTOPENIC PURPURA ON HEALTH-RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PDB29 PHARMACOECONOMIC EVALUATION OF CABERGOLINE FOR THE MANAGEMENT OF HYPERPROLACTINEMIA CAUSED BY HYPOPHYSEAL MICROADENOMA IN MEXICO

    May 1, 2008, 00:00

  • PRS1 COMPARISON OF THE EFFECTIVENESS OF ONE VERSUS TWO ANTIBIOTICS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA (CAP). AN ANALISYS USING PROPENSITY SCORE.

    May 1, 2008, 00:00

  • PMH15 ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS ASSOCIATED WITH ANTIPSYCHOTICS AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PCN37 PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE (ECX) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER

    May 1, 2008, 00:00

  • The Impact of Body Weight on Patient Utilities with or without Type 2 Diabetes- A Review of the Medical Literature

    May 1, 2008, 00:00

  • PDB31 COST-EFFECTIVENESS OF DETEMIRVERSUS NPH FORTYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN PORTUGAL

    May 1, 2008, 00:00

  • PMS42 A COMPARISON OF PROVINCIAL PRESCRIPTION-ONLY PHARMACEUTICAL DATABASE WITH SELF-REPORTED USAGE OF ACETAMINOPHEN AND NSAIDS ACCORDING TO OSTEOARTHRITIS STAGE IN BRITISH COLUMBIA

    May 1, 2008, 00:00

  • PRS15 THE BURDEN OF NASAL CONGESTION IN THE UNITED STATES

    May 1, 2008, 00:00

  • PCN4 DATA ANALYSIS WITH GENERALIZED LINEAR MODELS ON LUNG CANCER DATA

    May 1, 2008, 00:00

  • MD8 THE IMPACT OF MEDICARE NEW DRUG BENEFIT (PART D) ONTHE UTILIZATION OF PSYCHOTROPIC MEDICATIONS AND CONSEQUENT OUT OF POCKET EXPENDITURE FOR ELDERLY

    May 1, 2008, 00:00

  • PRS20 A LONG TERM COST-EFFECTIVENESS ANALYSIS MODEL FOR SMOKING CESSATION IN KOREA

    May 1, 2008, 00:00

  • PSS27 USING MEDICATION POSSESSION AND DAYS OF COVERAGE ON THERAPYTO ASSESS PERSISTENCE WITH PROSTAGLANDIN OCULAR HYPOTENSIVE THERAPY

    May 1, 2008, 00:00

  • PIN22 PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES FOR TREATING MILD DIABETIC FOOT INFECTIONS- A DECISION TREE MODEL FOR CANADA

    May 1, 2008, 00:00

  • PCN36 COST-MINIMIZATION ANALYSIS OF CAPECITABINE FOR ADVANCED GASTRIC CANCER IN TAIWAN

    May 1, 2008, 00:00

  • Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept- Continuous versus Interrupted Treatment

    May 1, 2008, 00:00

  • PCN21 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS-ANALYSIS STUDIES OF TRASTUZUMAB (HERCEPTIN) IN TREATMENT OF HER2-POSITIVE BREAST CANCER

    May 1, 2008, 00:00

  • PCV49 ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION AND AFTER MAJOR ORTHOPAEDIC SURGERY-RESULTS OF A SYSTEMATIC LITERATURE REVIEW

    May 1, 2008, 00:00

  • PHP47 ASSESSMENT OF NATIONAL MEDICARE PART D ESTIMATED ANNUAL COSTS FOR 2007 AND 2008 USING A PATIENT COHORT

    May 1, 2008, 00:00

  • PND15 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PCV46 COSTS OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY; 2003-2005

    May 1, 2008, 00:00

  • PDB50 INCREASED HOSPITALIZATIONS BY CHILDREN WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PDB36 HEALTH SERVICE COSTS AND RESOURCE UTILIZATION AMONG MANAGED CARE ENROLLEES WITH GOUT AND RENAL DISEASE

    May 1, 2008, 00:00

  • PMC29 INTERNATIONAL VALUATION SET FOR EQ-5D HEALTH STATES

    May 1, 2008, 00:00

  • PHP72 GENETIC TESTING FOR WARFARIN INITIATION- A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE

    May 1, 2008, 00:00

  • PMH66 ETHNICITY ANDTHE IMPACT OF HIGHER MEDICATION COPAYMENTS AMONGVETERANS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • AC2 PATTERNS OF DIABETES MEDICATION AND TEST ADHERENCE IN A MEDICAID DISEASE MANAGEMENT PROGRAM

    May 1, 2008, 00:00

  • PGI11 DIRECT COST SIMILARITIES BY POINT OF SERVICE FOR PERSONS WITH CONSTIPATION OR IRRITABLE BOWEL SYNDROME PLUS CONSTIPATION IN THE SIX MONTHS BEFORE AND AFTER DIAGNOSIS- AN EMPLOYER PERSPECTIVE

    May 1, 2008, 00:00

  • PSS26 USING COST-UTILITY ANALYSIS TO ASSESS THE BUDGET IMPACT OF BIOLOGICS FOR THE TREATMENT OF PSORIASIS (PSO)

    May 1, 2008, 00:00

  • PMC6 THE S ORIGINAL PAPER WITH AN EYE TOTHE FUTURE

    May 1, 2008, 00:00

  • CASE 2 DRUG ELUTING STENTS-AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES

    May 1, 2008, 00:00

  • PIH25 VARIATIONS IN ANTIPSYCHOTIC THERAPY AND SHORT-TERM MORTALITY ACROSS LONG-TERM CARE HOMES

    May 1, 2008, 00:00

  • PMC46 DEVELOPMENT OF A STANDARDIZED CLASSIFICATION SYSTEM FOR THE TRANSLATIONS OF PRO INSTRUMENTS

    May 1, 2008, 00:00

  • PCV95 IMPACT OF ADOPTION OF NEWANTIHYPERTENSIVE DRUGS ON THE HEALTH CARE UTILIZATION IN HYPERTENSIVE PATIENTS

    May 1, 2008, 00:00

  • PCN25 CONSIDERATIONS FOR MODELING THE COST-EFFECTIVENESS OF PREVENTATIVE PROSTATE CANCER TREATMENTS

    May 1, 2008, 00:00

  • PMS9 COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)AND INADEQUATE RESPONSE TO METHOTREXATE (MTX) ORTUMOR NECROSIS FACTOR-ALPHA INHIBITORS (ANTI-TNFS)-A CANADIAN PERSPECTIVE

    May 1, 2008, 00:00

  • PIN4 ANTIMICROBIAL RESISTANCE PREVALENCE OF ENTEROCOCCI FROM BOGOTA, COLOMBIA HOSPITALS 2001-2006

    May 1, 2008, 00:00

  • The Burden of Ankylosing Spondylitis in Spain

    May 1, 2008, 00:00

  • PDB30 A MODELLED COST-EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO INSULIN DETEMIR FROM ORAL ANTIDIABETICS OR NPH IN THE AUSTRIAN SETTING; DATA FROM THE PREDICTIVE STUDY

    May 1, 2008, 00:00

  • PRS30 USE OF INTERACTIVE VOICE RESPONSE (IVR)TO COLLECT DAILY PATIENT DIARY DATA IN A CLINICAL TRIAL OF SEASONAL RHINITIS

    May 1, 2008, 00:00

  • PIN46 COUNTRY ASSESSMENT TO DETERMINE FACTORS INFLUENCING THE COST, AVAILABILITY AND DISTRIBUTION OF ACYCLOVIR IN EIGHT SUB-SAHARAN AFRICAN COUNTRIES

    May 1, 2008, 00:00

  • PHP62 HOW EVIDENCE-BASED AND TIMELY ARE MEDICARE COVERAGE DECISIONS FOR NEWTECHNOLOGIES- AN EMPIRICAL ANALYSIS, 1999-2007

    May 1, 2008, 00:00

  • PCV6 ROLE OF OSTEOPROTEGERIN AND RANKL IN BONE AND VASCULAR CALCIFICATION

    May 1, 2008, 00:00

  • PCN26 COST-EFFECTIVENESS MODELING OF COLORECTAL CANCER I0YEARS SCREENING USING COMPUTEDTOMOGRAPHIC COLONOGRAPHYVERSUS COLONOSCOPY AND FECAL OCCULT BLOOD TESTS

    May 1, 2008, 00:00

  • PCN29 SCREENING, PREVENTION, AND TREATMENT OF CERVICAL CANCER-A GLOBAL AND REGIONAL GENERALIZED COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PCV57 PREVALENCE OF UNDERUTILIZATION OF INITIATED STATIN THERAPY AND RENIN-ANGIOTENSIN SYSTEM BLOCKADE

    May 1, 2008, 00:00

  • PHP69 THE PRESCRIBING OF CHINESE HERBAL PRODUCTS IN TAIWAN-A CROSS-SECTIONAL ANALYSIS OFTHE NATIONAL HEALTH INSURANCE REIMBURSEMENT DATABASE

    May 1, 2008, 00:00

  • PUK19 COMPARISON OF THE HEALTH-RELATED QUALITY OF LIFE BETWEEN PATIENTS UNDERGOING PERITONEAL DIALYSIS AND HAEMODIALYSIS

    May 1, 2008, 00:00

  • PCV55 THIRY-DAY RESOURCE USE DIARY DATA FROM THE BURST STUDY

    May 1, 2008, 00:00

  • PMH53 IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUGTHERAPY BY PATIENTS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PMS30 EFFECTS OF 12-HOUR, EXTENDED-RELEASE HYDROCODONE/ACETAMINOPHEN ON PAIN-RELATED WORK PRODUCTIVITY- A SUBANALYSIS FROM A 56-WEEK OPEN-LABEL STUDY

    May 1, 2008, 00:00

  • PMC31 CONTROLLING MEASUREMENT ERROR OF PATIENT-REPORTED-OUTCOMES DURING THE IMPLEMENTATION STAGE OF CLINICAL TRIALS

    May 1, 2008, 00:00

  • PMH39 THE PREVALENCE AND COSTS OF METABOLIC CONDITIONS AMONG PATIENTS WITH BIPOLAR DISORDERS AS COMPARED TO MATCHED CONTROLS

    May 1, 2008, 00:00

  • PIN31 TOTAL TREATMENT COST OF LINEZOLID COMPARED TO VANCOMYCIN IN MRSA INFECTIONS

    May 1, 2008, 00:00

  • PHP9 UNITED STATES PHYSICIANS AND IN-OFFICE DRUG ADMINISTRATION-THE CONCEPT OF 'INCIDENT-TO' SERVICES

    May 1, 2008, 00:00

  • IN2 UPPER RESPIRATORY ILLNESS AND EMPLOYEE PRODUCTIVITY-RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF)

    May 1, 2008, 00:00

  • PMH82 PREVALENCE AND PATTERNS OF NEWER ANTIDEPRSSANTS USED IN CHILDREN AND ADOLESCENTS IN A STATE MEDICAID PROGRAM OVER SEVENYEARS

    May 1, 2008, 00:00

  • PMC45 EQ-5D VAS = PRO

    May 1, 2008, 00:00

  • PRS38 HEALTH CARE UTILIZATION CORRELATED WITH CONTROLLER DURATION DURING THE FIRST YEAR AFTER DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2008, 00:00

  • PMS18 COST-EFFECTIVENESS OFABATACEPT IN PATIENTS WITH MODERATELYTO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE IN BRAZIL

    May 1, 2008, 00:00

  • PSS30 USTEKINUMAB SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH PSORIASIS- RESULTS FROM A PHASE III STUDY

    May 1, 2008, 00:00

  • PDB44 COST-EFFECTIVENESS OF THE USE OF ANGIOTENSIN-II-RECEPTER BLOCKERS IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY IN JAPAN

    May 1, 2008, 00:00

  • PIN50 INITIAL THERAPIES FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2008, 00:00

  • PIN24 COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN FOR THE MANAGEMENT OF INVASIVE CANDIDIASIS IN NON-NEUTROPENIC PATIENTS IN MEXICO

    May 1, 2008, 00:00

  • PIH15 STUDENT PHARMACIST INTERVENTIONS LEAD TO COST MINIMIZATION OF MEDICARE PART D PRESCRIPTION DRUG PLAN COSTS

    May 1, 2008, 00:00

  • PSS42 MAPPING THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE (NEI-VFQ 25) TO THE INDEX VALUES FOR THE EQ-5D-A COMPARISON OF MODELS

    May 1, 2008, 00:00

  • PDB51 A RESTROSPECTIVE ANALYSIS OF MEDICATIONS ADHERENCE AND ASSOCIATED HEALTH CARE COST FOR THE DIABETIC PATIENTS

    May 1, 2008, 00:00

  • PCN91 A PREVALENCE-BASED ECONOMIC ANALYSIS OF THE GROWTH IN CANCER TREATMENT SPENDING IN THE UNITED STATES

    May 1, 2008, 00:00

  • PMH27 COST-EFFECTIVENESS OF A MINIMAL INTERVENTION STRATEGY FOR STRESS-RELATED SICK LEAVE IN GENERAL PRACTICE- RESULTS OF AN ECONOMIC EVALUATION ALONGSIDE A PRAGMATIC RANDOMIZED CONTROLLED TRIAL

    May 1, 2008, 00:00

  • PSS18 COST-EFFECTIVENESS OF THE BIOLOGIC AGENTS UTILIZED IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS- A MARKOV MODEL

    May 1, 2008, 00:00

  • PSY13 THE HEALTH CARE COST EFFECTS OF DIABETES AMONG OBESE AND MORBIDLY OBESE ADULTS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PSY27 BURDEN OF OBESITY- 10-YEAR REVIEW OF PUBLISHED LITERATURE ON DIRECT AND INDIRECT COSTS IN NINE COUNTRIES

    May 1, 2008, 00:00

  • PHP79 PHYSICIAN QUALITY MEASUREMENT IN THE HEALTH PLAN PPO SETTING-THE IMPORTANCE OF SCORING ALGORITHMS

    May 1, 2008, 00:00

  • PMS26 TRENDS IN HOSPITALIZATIONS AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS-AN ANALYSIS OF 2002-2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA

    May 1, 2008, 00:00

  • PDB71 EVALUATION OF ECONOMIC OUTCOMES. ADHERENCE, AND GLYCEMIC CONTROL FOR DIABETIC PATIENTS IN A PHARMACIST-RUN MEDICATION MANAGEMENT PROGRAM

    May 1, 2008, 00:00

  • PMH56 THE IMPACT OF DULOXETINE, VENLAFAXINE AND ESCITALOPRAM USE AND PRESCRIPTION COPAYS ON MEDICATION PERSISTENCE, HEDIS MEASURES AND EXPENDITURES

    May 1, 2008, 00:00

  • CASE 5 THE CENTER FOR DRUG POLICY- PARTNERS HEALTHCARE

    May 1, 2008, 00:00

  • AC6 ASSOCIATION OF NONCOMPLIANCE WITH DIABETES CARE GUIDELINES AND DISEASE BURDEN IN A CALIFORNIA MEDICAID TYPE 2 DIABETES MELLITUS POPULATION

    May 1, 2008, 00:00

  • PSY6 THE PREVALENCE OF PAIN SYMPTOMS AMONG UNITED STATES ADULTS AGED 65 AND OLDER

    May 1, 2008, 00:00

  • PCN23 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS CAPECITABINE VERSUS CAPECITABINE ALONE IN THE SECOND LINE TREATMENT FOR BREAST CANCER TREATMENT

    May 1, 2008, 00:00

  • PCV18 FACTORS ASSOCIATED WITH RISK OF METABOLIC SYNDROME FOR US FIRST GENERATION ADOLESCENTS (AGES 12-17)

    May 1, 2008, 00:00

  • PMC53 PREVALENCE OF RESEARCH FOCUSED ON GENETICALLY-LINKED DISORDERS- WHERE HAVEWE BEEN AND WHERE AREWE GOING?

    May 1, 2008, 00:00

  • PSS2 EFFICACY OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS; META-ANALYSIS

    May 1, 2008, 00:00

  • PND21 COST-UTILITY OF PRAMIPEXOL COMPARED WITH L-DOPA/CARBIDOPA INTHE TREATMENT OF PARKINSONS DISEASE IN MEXICO

    May 1, 2008, 00:00

  • PND38 EVALUATION OF INTERVIEWER TRAINING FOR AN INTERVIEWER ADMINISTERED PATIENT-REPORTED OUTCOME IN A GLOBAL CLINICAL TRIAL

    May 1, 2008, 00:00

  • PHP56 COMPARATIVE ANALYSIS OF THE ACCESS TO PHARMACEUTICALS IN SELECTED EAST EUROPEAN COUNTRIES

    May 1, 2008, 00:00

  • PIN17 DECISION ANALYTIC MODEL EVALUATING THE COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT TISSUE INFECTION

    May 1, 2008, 00:00

  • PMH70 AN INVESTIGATION OF EVIDENCE-BASED USE OF ATYPICAL ANTIPSYCHOTICS IN ARKANSAS MEDICAID PEDIATRIC

    May 1, 2008, 00:00

  • PCV13 ANGINA FOLLOWING REVASCULARIZATION-FREQUENCY, PATIENT CHARACTERISTICS AND TIMING

    May 1, 2008, 00:00

  • PCV65 CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS

    May 1, 2008, 00:00

  • PCV81 ASSESSING THE IMPACT OF INCORPORATING PATIENT KNOWLEDGE AND BELIEFS INTO ANTICOAGULATION THERAPY MANAGEMENT SERVICES

    May 1, 2008, 00:00

  • PCN16 COST DIVERSITY OF DRG BASED COLORECTAL CANCER THERAPIES IN HUNGARY

    May 1, 2008, 00:00

  • PMC17 A METHOD FOR CONVERTING NATIONAL DRUG CODES (NDCS) TO GENERIC ANDTHERAPEUTIC CATEGORY CODES FOR USE IN LARGE DATABASE STUDIES OF PRESCRIPTION DRUG CLAIMS

    May 1, 2008, 00:00

  • PCN38 THE IMPACT OF BREAST CANCER CARE DEVELOPMENT ON MEDICAL AND ECONOMICAL OUTCOMES IN ATOTAL SOCIETAL COST CONTEXT

    May 1, 2008, 00:00

  • PCV83 GENDER DISPARITIES IN THE UTILIZATION OF MYOCARDIAL PERFUSION IMAGING

    May 1, 2008, 00:00

  • WH2 DISABILITY AND ASSOCIATED COSTS AMONGWOMEN WITH EMPLOYER-SPONSORED INSURANCE AND NEWLY DIAGNOSED BREAST CANCER

    May 1, 2008, 00:00

  • PMS37 ASSESSING THE VALIDITY AND RELIABILITY OF A SIMPLE ACTIVITY PARTICIPATION MEASURE FOR RHEUMATOID ARTHRITIS CLINICAL TRIALS

    May 1, 2008, 00:00

  • PCN88 FACTORS ASSOCIATED WITH THE PRESCRIPTION OF ADJUVANT HORMONAL THERAPIES AMONG MEDICAID ENROLLEESWITH BREAST CANCER

    May 1, 2008, 00:00

  • PMS16 ECONOMIC EVALUATION OF MONTHLY IBANDRONATE VS WEEKLY ALENDRONATE TO PREVENT OSTEOPOROTIC HIP FRACTURES IN MEXICAN WOMEN AGED FIFTY AND OLDER

    May 1, 2008, 00:00

  • PDB13 PREDICTING INPATIENT HOSPITALIZATION RISKS FOR MEDICAID DIABETES PATIENTS

    May 1, 2008, 00:00

  • PMS11 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB FOR RHEUMATOID ARTHRITIS IN TAIWAN

    May 1, 2008, 00:00

  • PIN34 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CHRONIC HEPATITIS C IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PMC19 ESTIMATING SOCIODEMOGRAPHIC VARIABLES IN A PHARMACY DATASET- APPLYING DATA FROM US CENSUS 2000

    May 1, 2008, 00:00

  • Cost-Utility Analysis of Rimonabant in the Treatment of Obesity

    May 1, 2008, 00:00

  • PGI2 HOSPITALIZATIONS FOR GASTROINTESTINAL EVENTS AMONG USERS OF COX 2 INHIBITORS COMPARED WITH TRADITIONAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS WITH PROTON-PUMP INHIBITORS

    May 1, 2008, 00:00

  • PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY

    May 1, 2008, 00:00

  • PCN1 DIAGNOSIS OF HER2 PROTEIN OVEREXPRESSION IN PATIENTS WITH BREAST CANCER IN BRAZIL

    May 1, 2008, 00:00

  • PUK3 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION THAT MAY REQUIRE DRUG DOSAGE ADJUSTMENT

    May 1, 2008, 00:00

  • PDB52 SYSTEMATIC REVIEW OF ADHERENCE, COMPLIANCE AND QUALITY OF LIFE IN TYPE 2 DIABETES PATIENTS

    May 1, 2008, 00:00

  • PMC5 AN ANATOMY OF PHARMACEUTICAL COST-UTILITY ANALYSES, 1976-2005

    May 1, 2008, 00:00

  • PHP5 ADHERENCE AND SWITCHING WITH DRUGS USED FOR THE PROPHYLAXIS OF ORGAN REJECTION

    May 1, 2008, 00:00

  • PCV50 UP-TITRATION OF STATIN THERAPY TO MEET CANADIAN TARGET LIPID GOALS- ECONOMIC IMPACT OFTITRATION ASSOCIATED WITH COMPARATIVE EFFICACY OF ROSUVASTATIN, ATORVASTATIN, SIMVASTATIN AND PRAVASTATIN

    May 1, 2008, 00:00

  • PCV61 IMPACT OF PRESCRIPTION COPAY ON ADHERENCE WITH RENIN-ANGIOTENSIN SYSTEM AGENTS IN HEART FAILURE PATIENTS

    May 1, 2008, 00:00

  • PMH4 ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIAS BAYESIAN META-ANALYSIS OF DIRECT AND INDIRECT COMPARISONS

    May 1, 2008, 00:00

  • PSS43 WORK RELATED LOST PRODUCTIVITY AND ITS ECONOMIC IMPACT IN CANADIAN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    May 1, 2008, 00:00

  • PDB8 DEFINING HYPOGLYCEMIA AND ASSESSING ITS AFFECT ON OUTCOMES IN THE HOSPITAL SETTING

    May 1, 2008, 00:00

  • PSY28 A SYSTEMATIC REVIEW OF LOW BACK PAIN COST OF ILLNESS STUDIES IN THE UNITED STATES AND INTERNATIONALLY

    May 1, 2008, 00:00

  • PND20 ECONOMIC CONSEQUENCES OF MULTIPLE SCLEROSIS- A POPULATION-BASED STUDY

    May 1, 2008, 00:00

  • Reliability of Two Instruments for Critical Assessment of Economic Evaluations

    May 1, 2008, 00:00

  • PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO

    May 1, 2008, 00:00

  • PGI26 FINANCIAL IMPACT OF LIFTING A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR CHRONIC CONSTIPATION PATIENTS IN A COMMERCIAL MANAGED CARE POPULATION (AGE 65 YEARS)

    May 1, 2008, 00:00

  • PMS6 BUDGET IMPACT ANALYSIS OFABATACEPT INCLUSION FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE BRAZILIAN PUBLIC SYSTEM

    May 1, 2008, 00:00

  • PIH20 PREDICTING RISK OF WORK LOSS ASSOCIATED WITH PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER USING MENTAL COMPONENT SUMMARY (MCS) SCORE

    May 1, 2008, 00:00

  • PGI18 LINGUISTIC VALIDATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) IN 35 LANGUAGES

    May 1, 2008, 00:00

  • PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA

    May 1, 2008, 00:00

  • PIN44 ANTIBIOTIC PRESCRIBING IN THE HOSPITAL EMERGENCY DEPARTMENT

    May 1, 2008, 00:00

  • PRS45 THE DEVELOPMENT AND VALIDATION OF A CONTEMPORARY ASTHMA POLICY MODEL

    May 1, 2008, 00:00

  • PSS21 COST OF ILLNESS OF WORK-RELATED CHRONIC HAND ECZEMA IN GERMANY

    May 1, 2008, 00:00

  • Time and Expected Value of Sample Information Wait for No Patient

    May 1, 2008, 00:00

  • PRS28 ADHERENCE TO INHALED CORTICOSTEROID USE AND LOCAL ADVERSE EVENTS IN PERSISTENT ASTHMA

    May 1, 2008, 00:00

  • PMH78 EFFECTS OF DIRECT-TO-CONSUMER ADVERTISING AND DETAILING SPENDING ON ANTIDEPRESSANT SWITCH AND TREATMENT COMPLETION

    May 1, 2008, 00:00

  • PIH27 GENERIC SUBSTITUTION OF WARFARIN AMONG THE ELDERLY- AN EXAMINATION OF HOSPITAL AND EMERGENCY ROOM USE

    May 1, 2008, 00:00

  • DU3 CALIFORNIA WILDFIRES ANDTHEIR IMPACT ON MEDICATION ACQUISITION

    May 1, 2008, 00:00

  • PMH8 TREATMENT DURATION FOLLOWING INITIATION ON ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIA PATIENTS WITH VERSUS WITHOUT A METABOLIC SYNDROME

    May 1, 2008, 00:00

  • PUK7 COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE REGIMENS IN RENAL TRANSPLANT RECIPIENTS IN GERMANY

    May 1, 2008, 00:00

  • PDB67 DESCRIPTIVE ANALYSIS OF BODY WEIGHT AND CLINICAL EFFECTIVENESS MEASURES ASSOCIATED WITH TYPE 2 DIABETES THERAPIES IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE

    May 1, 2008, 00:00

  • PMH65 EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE- POPULATION-BASED NATURAL EXPERIMENT

    May 1, 2008, 00:00

  • PMS3 EFFICACY OF COX-2 SELECTIVE NSAIDS, NON-SELECTIVE NSAIDS, AND ACETAMINOPHEN IN OSTEOARTHRITIS- A BAYESIAN MIXED TREATMENT COMPARISON

    May 1, 2008, 00:00

  • PND16 THE CONCENTRATION AND PERSISTENCE OF HEALTH CARE EXPENDITURES AND PRESCRIPTION DRUG EXPENDITURES IN PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2008, 00:00

  • PCV10 EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON CHD EVENTS IN A SECONDARY PREVENTION POPULATION WITH HIGH NON-HDL CHOLESTEROL

    May 1, 2008, 00:00

  • PGI20 PARTIAL RESPONDERS TO PPI TREATMENT; HOW DO THEY DIFFER FROM OTHER GERD PATIENTS IN TERMS OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILISATION?-A DATABASE ANALYSIS

    May 1, 2008, 00:00

  • PMC11 ACCOUNTING FOR THE PLACEBO RESPONSE IN COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PMC1 SEARCH STRATEGIES AND RESULTS OF SYSTEMATIC REVIEWS

    May 1, 2008, 00:00

  • PMC49 TRANSLATING HETEROGENEITY BIAS FROM HEALTH STATUS IN OUTCOMES STUDIES-USING LATENT CLASS CLUSTER ANALYSIS AND LONGITUDINAL DATA

    May 1, 2008, 00:00

  • PMC9 30 YEARS OF COST-EFFECTIVENESS ANALYSES-A BIBLIOMETRIC REVIEW OF ARTICLES PUBLISHED IN THE ECONOMIC AND MEDICAL LITERATURE- 1976-2005

    May 1, 2008, 00:00

  • PSS8 ESTIMATING COST-EFFECTIVENESS OF TOPICAL OCULAR HYPOTENSIVES FOR MAINTAINING PERSISTENT THERAPY USING AREA UNDERTHE SURVIVAL CURVE

    May 1, 2008, 00:00

  • PIN21 COST-EFFECTIVENESS OF ANIDULAFUNGIN THERAPY IN CONFIRMED CANDIDEMIA AND OTHER FORMS OF INVASIVE CANDIDIASIS IN CANADA

    May 1, 2008, 00:00

  • PDB38 PREVALENCE OF OTHER DIABETES-ASSOCIATED COMPLICATIONS AND ITS IMPACT ON HEALTH CARE CHARGES AMONG PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • PSS32 QUALITY OF LIFE AND PSYCOLOGICAL DISTRESS IN PATIENT WITH CUTANEUOS LYMPHOMA

    May 1, 2008, 00:00

  • PND24 IMPACT OF NON-ADHERENCE TO ANTIEPILEPTIC DRUGS ON MORBIDITY

    May 1, 2008, 00:00

  • PCV56 VOLUME AND MIX OF CARDIAC X-RAY PROCEDURES ACROSS U.S. HOSPITALS- UTILIZATION DATA TO SUPPORT FINANCIAL DECISIONS

    May 1, 2008, 00:00
  • «
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150 (current)
  • »